<DOC> 
<DOCNO>1040515_business_story_3250135.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Saturday, May 15, 2004 				 Biocon net leaps 219% to Rs 138.6 crore
 OUR CORRESPONDENT 				 	 Shaw in Bangalore on Friday. (AFP)																								Mumbai, May 14: Biocon Ltd has recorded a 219 per cent rise in net profit at Rs 138.6 crore for the year ended March 31, 2004 compared with Rs 43.5 crore posted in the previous fiscal.																								Total income shot up by 94 per cent to Rs 549.3 crore in the last fiscal over Rs 283.3 crore a year earlier. This included sales of Rs 501.88 crore (Rs 253.81 crore) and contract research that contributed Rs 38.7 crore (Rs 27.8 crore). Other income was also higher at Rs 8.6 crore from Rs 1.6 crore in the previous fiscal.																								The board of directors has announced a 20 per cent dividend for 2003-04. Earnings per share stood at Rs 16 for the year.																								Operating margins were higher by 654 basis points at 33 per cent in the reporting year. Chairman and managing director Kiran Mazumdar-Shaw said that Biocons businesses, including statins, enzymes and research services, reported an exceptional growth. 																								Our outlook for the year ahead is very positive. We expect substantial growth to be delivered by sales of pravastatin to Europe and from our new products, including insulin, immuno suppressants and branded formulations. Research services will also be a key growth driver, Shaw said.																								Biocon has entered into an agreement to supply recombinant human insulin in bulk form to Bristol Myers Squibb Co. It is the first Indian company to have filed a drug master file with the US FDA for this insulin.																								While the contract is for a period of nine years, the Bangalore-based company is also planning to sell recombinant human insulin in India under the brand name Insugen by the second quarter of this year.																								The company has received US FDAs approval for pravastatin, simvastatin, lovastatin and pioglitazone manufacturing facilities. This approval gives Biocon access to the US market valued at $6 billion which is slated to go off-patent in 2006. Biocon exports lovastatin to the US and simvastatin to Europe.																								In the last financial year, Biocons revenues from biopharmaceuticals business increased 117 per cent to Rs 435.4 crore from Rs 200.7 crore in the previous fiscal. Revenues from statins increased 153 per cent to Rs 302.8 crore (Rs 119.9 crore).ITC Hotels																								ITC Hotels has posted a 170 per cent rise in net profit at Rs 11.65 crore for the fourth quarter ended March 31, 2004 against Rs 4.32 crore posted in the corresponding previous quarter.																								Total income also went up 32 per cent to Rs 51.97 crore in the reporting quarter from Rs 39.23 crore in the year-ago period. 
</TEXT> 
</DOC>